期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (7)
IntroductionSystemic sclerosis (SSc) is an orphan, chronic, autoimmune, fibrotic disease with unknown etiology characterized by progressive fibrosis o......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (9)
IntroductionExcessive activity of neutrophil elastase (NE), the main enzyme present in azurophil granules in the neutrophil cytoplasm, may cause tissu......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (10)
BackgroundSB16 is a biosimilar to reference denosumab (DEN). This study assessed pharmacokinetic (PK) equivalence and evaluated pharmacodynamic (PD), ......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (12)
Introduction: Idiopathic intracranial hypertension is a neurological condition characterized by a raised intracranial pressure and papilledema that ca......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (7)
Introduction Sensorineural hearing loss results in irreversible loss of inner ear hair cells and spiral ganglion neurons. Reduced sound detection and ......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (2)
IntroductionDiabetes affects 400 million people globally and patients and causes nephropathy, neuropathy, and vascular disease. Amongst these complica......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (6)
IntroductionOral mucositis (OM) remains a significant, highly symptomatic, disruptive side effect of radiation and concomitant chemoradiation therapy ......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (9)
IntroductionHypertrophic cardiomyopathy (HCM), a phenotypically variable disorder with a genetic basis, was first described in the late 1800s. Since t......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (1)
IntroductionFriedreich ataxia (FRDA) is a rare autosomal recessive degenerative disorder characterized by ataxia, dysarthria, diabetes, cardiomyopathy......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; ()
IntroductionThere has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have ......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (7)
IntroductionErectile dysfunction (ED) is a condition that affects millions of men worldwide and is characterized by the inability to achieve or mainta......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (5)
IntroductionThe Leukemia Inhibitory Factor (LIF) is a member of the interleukin-6 (IL-6) cytokine family. Known to induce differentiation of myeloid l......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (2)
IntroductionAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by motoneuron death with a median survival time of 3-5 years si......
期刊： EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023; 32 (3)
BackgroundDasatinib (Sprycel (R)) is a tyrosine kinase inhibitor for treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymp......
